Alternative agents to vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections

American Journal of Therapeutics

Volumn 20, Issue 2, 2013, Pages 200-212

  Culos, Kathryn A ^a   Cannon, Joan P ^b   Grim, Shellee A ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b Division of Centocor Ortho Biotech Services LLC   (United States)

Author keywords

Ceftaroline; Daptomycin; Linezolid; Quinupristin dalfopristin; Televancin; Tigecycline

Indexed keywords

ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; CALCIUM CHANNEL BLOCKING AGENT; CEFTAROLINE; CEFTAROLINE FOSAMIL; CEFTOBIPROLE; CEFTRIAXONE; DALBAVANCIN; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; DELAFLOXACIN; FINAFLOXACIN; IMMUNOSUPPRESSIVE AGENT; LINEZOLID; ORITAVANCIN; RADEZOLID; TEDIZOLID; TELAVANCIN; TIGECYCLINE; VANCOMYCIN;

ANEMIA; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC THERAPY; ARTHRALGIA; BACTEREMIA; BACTERIAL ENDOCARDITIS; BLOODSTREAM INFECTION; CONSTIPATION; DIARRHEA; DRUG COST; DRUG EFFICACY; DRUG INDICATION; DRUG INDUCED HEADACHE; DRUG POTENCY; DRUG POTENTIATION; DRUG RESPONSE; DRUG SAFETY; HEADACHE; HUMAN; INJECTION SITE INFLAMMATION; INJECTION SITE IRRITATION; INJECTION SITE PAIN; INTERNATIONAL NORMALIZED RATIO; LEUKOPENIA; LOADING DRUG DOSE; MAINTENANCE DRUG DOSE; MAINTENANCE THERAPY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MYALGIA; NAUSEA; NEPHROTOXICITY; NONHUMAN; OPTIC NERVE DISEASE; OSTEOMYELITIS; PERIPHERAL NEUROPATHY; PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMONIA; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; REVIEW; SIDE EFFECT; SKIN INFECTION; TASTE DISORDER; THROMBOCYTOPENIA; VOMITING; VRE,;

ANIMALS; ANTI-BACTERIAL AGENTS; DRUG DESIGN; HUMANS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; STAPHYLOCOCCAL INFECTIONS; VANCOMYCIN;

EID: 84875212907     PISSN: 10752765     EISSN: 15363686     Source Type: Journal    
DOI: 10.1097/MJT.0b013e31821109ec     Document Type: Review

References (91)

1. Klevens RM, Edwards JR, Richards CL Jr, et al. Estimating health care-Associated infections and deaths in U.S. hospitals, 2002. Public Health Rep. 2007;122:160-166
2. Klevens RM, Edwards JR, Tenover FC, et al. Changes in the epidemiology of methicillin-resistant Staphylococcus aureus in intensive care units in US hospitals, 1992-2003. Clin Infect Dis. 2006;42:389-391
3. Naimi TS, LeDell KH, Como-Sabetti K, et al. Comparison of community-And health care-Associated methicillinresistant Staphylococcus aureus infection. JAMA. 2003;290: 2976-2984
4. Kallen AJ, Mu Y, Bulens S, et al. Health care-Associated invasive MRSA infections, 2005-2008. JAMA. 2010;304: 641-648
5. Anderson DJ, Kaye KS, Chen LF, et al. Clinical and financial outcomes due to methicillin resistant Staphylococcus aureus surgical site infection: A multi-center matched outcomes study. PLoS One. 2009;4:e8305
6. Cosgrove SE, Sakoulas G, Perencevich EN, et al. Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: A meta-Analysis. Clin Infect Dis. 2003;36:53-59
7. Moisan H, Pruneau M, Malouin F. Binding of ceftaroline to penicillin-binding proteins of Staphylococcus aureus and Streptococcus pneumoniae. J Antimicrob Chemother. 2010;65: 713-716
8. Guidelines for the management of adults with hospitalacquired, ventilator-Associated, and healthcare-Associated pneumonia. Am J Respir Crit Care Med. 2005;171: 388-416
9. Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft-Tissue infections. Clin Infect Dis. 2005;41:1373-1406
10. Vancomycin [package insert]. Lake Forest, IL: Hospira, Inc.; 2007
11. Arbeit RD, Maki D, Tally FP, et al. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin Infect Dis. 2004;38: 1673-1681
12. Arhin FF, Draghi DC, Pillar CM, et al. Comparative in vitro activity profile of oritavancin against recent grampositive clinical isolates. Antimicrob Agents Chemother. 2009;53:4762-4771
13. Corey GR,Wilcox M, Talbot GH, et al. Integrated analysis of CANVAS 1 and 2: Phase 3, multicenter, randomized, double-blind studies to evaluate the safety and efficacy of ceftaroline versus vancomycin plus aztreonam in complicated skin and skin-structure infection. Clin Infect Dis. 2010;51:641-650
14. Draghi DC, Benton BM, Krause KM, et al. In vitro activity of telavancin against recent Gram-positive clinical isolates: Results of the 2004-05 Prospective European Surveillance Initiative. J Antimicrob Chemother. 2008;62: 116-121
15. Ellis-Grosse EJ, Babinchak T, Dartois N, et al. The efficacy and safety of tigecycline in the treatment of skin and skinstructure infections: Results of 2 double-blind phase 3 comparison studies with vancomycin-Aztreonam. Clin Infect Dis. 2005;41(suppl 5):S341-S353
16. Farrell DJ, Mendes RE, Ross JE, et al. Linezolid surveillance program results for 2008 (LEADER Program for 2008). Diagn Microbiol Infect Dis. 2009;65:392-403
17. Florescu I, Beuran M, Dimov R, et al. Efficacy and safety of tigecycline compared with vancomycin or linezolid for treatment of serious infections with methicillin-resistant Staphylococcus aureus or vancomycin-resistant enterococci: A Phase 3, multicentre, double-blind, randomized study. J Antimicrob Chemother. 2008;62(suppl 1):i17-i28
18. Fowler VG Jr, Boucher HW, Corey GR, et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med. 2006;355: 653-665
19. Fritsche TR, Sader HS, Jones RN. Antimicrobial activity of ceftobiprole, a novel anti-methicillin-resistant Staphylococcus aureus cephalosporin, tested against contemporary pathogens: Results from the SENTRY Antimicrobial Surveillance Program (2005-2006). Diagn Microbiol Infect Dis. 2008;61:86-95
20. Ge Y, Biek D, Talbot GH, et al. In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States. Antimicrob Agents Chemother. 2008;52:3398-3407
21. Giamarellou H, O'RiordanW, Harris H, et al. Phase III trial comparing 3-7 days of oritavancin versus 10-14 days of vancomycin/cephalexin in the treatment of patients with skin/skin structure infections (CSSI). 43rd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL: American Society of Microbiology; 2003
22. Krause KM, Renelli M, Difuntorum S, et al. In vitro activity of telavancin against resistant gram-positive bacteria. Antimicrob Agents Chemother. 2008;52:2647-2652
23. Kunkel M, Chastre JE, Kollef MH, et al. Linezolid vs. vancomycin in the treatment of nosocomial pneumonia proven due to methicillin-resistant Staphylococcus aureus. 48th Annual Meeting of the Infectious Diseases Society of America. Vancouver, British Columbia, Canada: Infectious Diseases Society of America; 2010
24. Noel GJ, Bush K, Bagchi P, et al. A randomized, doubleblind trial comparing ceftobiprole medocaril with vancomycin plus ceftazidime for the treatment of patients with complicated skin and skin-structure infections. Clin Infect Dis. 2008;46:647-655
25. Noel GJ, Strauss RS, Amsler K, et al. Results of a doubleblind, randomized trial of ceftobiprole treatment of complicated skin and skin structure infections caused by gram-positive bacteria. Antimicrob Agents Chemother. 2008;52:37-44
26. Pankuch GA, Applebaum PC. Oritavancin activity against 200 vancomycin-susceptible and non-susceptible MRSA by MIC testing. 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society of Microbiology; 2008
27. Rubinstein E, Cammarata S, Oliphant T, et al. Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: A randomized, double-blind, multicenter study. Clin Infect Dis. 2001;32:402-412
28. Rubinstein E, Corey GR, Stryjewski ME, et al. Televancin for the treatment of hospital acquired pneumonia (HAP) caused by MRSA and MSSA. 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society of Microbiology; 2008
29. Sader HS, Fritsche TR, Kaniga K, et al. Antimicrobial activity and spectrum of PPI-0903M (T-91825), a novel cephalosporin, tested against a worldwide collection of clinical strains. Antimicrob Agents Chemother. 2005;49: 3501-3512
30. Saravolatz LD, Pawlak J, Johnson LB. In vitro activity of oritavancin against community-Associated methicillinresistant Staphylococcus aureus (CA-MRSA), vancomycinintermediate S. aureus (VISA), vancomycin-resistant S. aureus (VRSA) and daptomycin-non-susceptible S. aureus (DNSSA). Int J Antimicrob Agents. 2010;36:69-72
31. Stryjewski ME, Graham DR, Wilson SE, et al. Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by gram-positive organisms. Clin Infect Dis. 2008;46:1683-1693
32. Wasilewski MM, Disch D, Mcgill JM, et al. Equivalence of shorter course therapy with ortiavancin vs. vancomycin/ cephalexin in complicated skin/skin structure infections (CSSI). 41st Annual Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL: American Society of Microbiology; 2001
33. Weigelt J, Itani K, Stevens D, et al. Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections. Antimicrob Agents Chemother. 2005;49: 2260-2266
34. Wunderink RG, Cammarata SK, Oliphant TH, et al. Continuation of a randomized, double-blind, multicenter study of linezolid versus vancomycin in the treatment of patients with nosocomial pneumonia. Clin Ther. 2003;25: 980-992
35. Wunderink RG, Rello J, Cammarata SK, et al. Linezolid vs vancomycin: Analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia. Chest. 2003;124:1789-1797
36. Gould IM. Clinical relevance of increasing glycopeptide MICs against Staphylococcus aureus. Int J Antimicrob Agents. 2008;31(suppl 2):1-9
37. Rodriguez-Morales AJ, Rodriguez CN, Garcia A, et al. Surveillance analysis of decreasing susceptibility of Staphylococcus aureus to vancomycin using a mathematical model. Int J Antimicrob Agents. 2007;29:607-609
38. Steinkraus G, White R, Friedrich L. Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001-05. J Antimicrob Chemother. 2007;60:788-794
39. Wang G, Hindler JF, Ward KW, et al. Increased vancomycin MICs for Staphylococcus aureus clinical isolates from a university hospital during a 5-year period. J Clin Microbiol. 2006;44:3883-3886
40. Tenover FC, Moellering RC Jr. The rationale for revising the Clinical and Laboratory Standards Institute vancomycin minimal inhibitory concentration interpretive criteria for Staphylococcus aureus. Clin Infect Dis. 2007;44: 1208-1215
41. Rybak M, Lomaestro B, Rotschafer JC, et al. Therapeutic monitoring of vancomycin in adult patients: A consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm. 2009;66:82-98
42. Hermsen ED, Hanson M, Sankaranarayanan J, et al. Clinical outcomes and nephrotoxicity associated with vancomycin trough concentrations during treatment of deep-seated infections. Expert Opin Drug Saf. 2010;9:9-14
43. Synercid [package insert]. Briston, TN: Nonarch Pharmaceuticals Inc.; 2003
44. Jones RN, Ballow CH, Biedenbach DJ, et al. Antimicrobial activity of quinupristin-dalfopristin (RP 59500, Synercid) tested against over 28,000 recent clinical isolates from 200 medical centers in the United States and Canada. Diagn Microbiol Infect Dis. 1998;31:437-451
45. Lina G, Quaglia A, Reverdy ME, et al. Distribution of genes encoding resistance to macrolides, lincosamides, and streptogramins among staphylococci. Antimicrob Agents Chemother. 1999;43:1062-1066
46. Drew RH, Perfect JR, Srinath L, et al. Treatment of methicillin-resistant staphylococcus aureus infections with quinupristin-dalfopristin in patients intolerant of or failing prior therapy. For the Synercid Emergency-Use Study Group. J Antimicrob Chemother. 2000;46:775-784
47. Raad I, Hachem R, Hanna H. Relationship between myalgias/arthralgias occurring in patients receiving quinupristin/dalfopristin and biliary dysfunction. J Antimicrob Chemother. 2004;53:1105-1108
48. Zyvox [package insert]. New York, NY: Pfizer, Inc.; 2009
49. Xiong L, Kloss P, Douthwaite S, et al. Oxazolidinone resistance mutations in 23S rRNA of Escherichia coli reveal the central region of domain Vas the primary site of drug action. J Bacteriol. 2000;182:5325-5331
50. ZhuW, Tenover FC, Limor J, et al. Use of pyrosequencing to identify point mutations in domain V of 23S rRNA genes of linezolid-resistant Staphylococcus aureus and Staphylococcus epidermidis. Eur J Clin Microbiol Infect Dis. 2007;26:161-165
51. Sanchez Garcia M, De la Torre MA, Morales G, et al. Clinical outbreak of linezolid-resistant Staphylococcus aureus in an intensive care unit. JAMA. 2010;303:2260-2264
52. Kehrenberg C, Aarestrup FM, Schwarz S. IS21-558 insertion sequences are involved in the mobility of the multiresistance gene cfr. Antimicrob Agents Chemother. 2007;51:483-487
53. Kehrenberg C, Schwarz S, Jacobsen L, et al. A new mechanism for chloramphenicol, florfenicol and clindamycin resistance: Nethylation of 23S ribosomal RNA at A2503. Mol Microbiol. 2005;57:1064-1073
54. Nosocomial pneumonia with suspected or proven methicillin-resistant Staphylococcus aureus (MRSA) (ZEPHYR) [U.S. National Institutes of Health website]. July 6, 2010. Available at: Http://www.clinicaltrials. gov/ct2/show/NCT00084266?term=linezolid+and+vancomycin& rank=3. Accessed October 1, 2010
55. Rubinstein E, Isturiz R, Standiford HC, et al. Worldwide assessment of linezolid's clinical safety and tolerability: Comparator-controlled phase III studies. Antimicrob Agents Chemother. 2003;47:1824-1831
56. Narita M, Tsuji BT, Yu VL. Linezolid-Associated peripheral and optic neuropathy, lactic acidosis, and serotonin syndrome. Pharmacotherapy. 2007;27:1189-1197
57. Reck F, Zhou F, Girardot M, et al. Identification of 4-substituted 1,2,3-Triazoles as novel oxazolidinone antibacterial agents with reduced activity against monoamine oxidase A. J Med Chem. 2005;48:499-506
58. Isbister GK, Buckley NA. The pathophysiology of serotonin toxicity in animals and humans: Implications for diagnosis and treatment. Clin Neuropharmacol. 2005;28: 205-214
59. Cubicin [package insert]. Lexington, MA: Cubist Pharmaceuticals; 2010
60. Sader HS, Jones RN. Antimicrobial susceptibility of Gram-positive bacteria isolated from US medical centers: Results of the Daptomycin Surveillance Program (2007-2008). Diagn Microbiol Infect Dis. 2009;65:158-162
61. Silverman JA, Mortin LI, Vanpraagh AD, et al. Inhibition of daptomycin by pulmonary surfactant: In vitro modeling and clinical impact. J Infect Dis. 2005;191:2149-2152
62. Tygacil [package insert]. Philadelphia, PA: Wyeth Ayerst Pharmaceutical; 2010
63. Mendes RE, Sader HS, Deshpande L, et al. Antimicrobial activity of tigecycline against community-Acquired methicillin-resistant Staphylococcus aureus isolates recovered from North American medical centers. Diagn Microbiol Infect Dis. 2008;60:433-436
64. Dowzicky MJ, Park CH. Update on antimicrobial susceptibility rates among gram-negative and grampositive organisms in the United States: Results from the Tigecycline Evaluation and Surveillance Trial (TEST) 2005 to 2007. Clin Ther. 2008;30:2040-2050
65. Babinchak T, Ellis-Grosse E, Dartois N, et al. The efficacy and safety of tigecycline for the treatment of complicated intra-Abdominal infections: Analysis of pooled clinical trial data. Clin Infect Dis. 2005;41(suppl 5):S354-S367
66. Conte JE Jr, Golden JA, Kelly MG, et al. Steady-state serum and intrapulmonary pharmacokinetics and pharmacodynamics of tigecycline. Int J Antimicrob Agents. 2005;25:523-529
67. Peleg AY, Potoski BA, Rea R, et al. Acinetobacter baumannii bloodstream infection while receiving tigecycline: A cautionary report. J Antimicrob Chemother. 2007;59:128-131
68. Vibativ [package insert]. Deerfield, IL: Astellas Pharma US, Inc.; 2009
69. Teflaro [package insert]. St. Louis, MS: Forest Pharmaceuticals; 2010
70. Hebeisen P, Heinze-Krauss I, Angehrn P, et al. In vitro and in vivo properties of Ro 63-9141, a novel broad-spectrum cephalosporin with activity against methicillin-resistant staphylococci. Antimicrob Agents Chemother. 2001;45: 825-836
71. Entenza JM, Hohl P, Heinze-Krauss I, et al. BAL9141, a novel extended-spectrum cephalosporin active against methicillin-resistant Staphylococcus aureus in treatment of experimental endocarditis. Antimicrob Agents Chemother. 2002;46:171-177
72. Eckburg P, Friedland HD, Lee J, et al. FOCUS 1 and 2: Randomised, double-blinded, multicenter phase 3 trials of the efficacy and safety of ceftaroline (CPT) vs ceftriaxone (CRO) in community-Acquired pneumonia (CAP). 49th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA: American Society of Microbiology; 2009
73. Forest announces FDA approval of Teflaro (ceftaroline fosamil) for the treatment of community-Acquired bacterial pneumonia and acute bacterial skin and skin structure infection [Pharmacy Choice web site]. November 15, 2010. Available at: Http://www.pharmacychoice.com/ News/article.cfm?Article-ID = 650247. Accessed November 22, 2010
74. Howe RA, Wootton M, Noel AR, et al. Activity of AZD2563, a novel oxazolidinone, against Staphylococcus aureus strains with reduced susceptibility to vancomycin or linezolid. Antimicrob Agents Chemother. 2003;47: 3651-3652
75. Zeftera [package insert]. Toronto, Ontario: Janssen-Ortho Inc.; 2008
76. Allen NE, Nicas TI. Mechanism of action of oritavancin and related glycopeptide antibiotics. FEMS Microbiol Rev. 2003;26:511-532
77. Belley A, McKay GA, Arhin FF, et al. Oritavancin disrupts membrane integrity of Staphylococcus aureus and vancomycin-resistant enterococci to effect rapid bacterial killing. Antimicrob Agents Chemother. 2010;54:5369-5371
78. Guskey MT, Tsuji BT. A comparative review of the lipoglycopeptides: Oritavancin, dalbavancin, and telavancin. Pharmacotherapy. 2010;30:80-94
79. Biedenbach DJ, Bell JM, Sader HS, et al. Activities of dalbavancin against a worldwide collection of 81,673 gram-positive bacterial isolates. Antimicrob Agents Chemother. 2009;53:1260-1263
80. Andes D, Craig WA. In vivo pharmacodynamic activity of the glycopeptide dalbavancin. Antimicrob Agents Chemother. 2007;51:1633-1642
81. Jauregui LE, Babazadeh S, Seltzer E, et al. Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections. Clin Infect Dis. 2005;41:1407-1415
82. Pfizer will withdraw global marketing applications for Dalbavancin to conduct a new trial [Medical News Today web site]. September 11, 2008. Available at: Http://www. medicalnewstoday.com/articles/121126.php. Accessed October 1, 2010
83. The uptake of two emerging agents from Forest/Astra-Zeneca/Takeda and Trius will drive the MRSA drug market to increase from $631 million in 2009 to $752 million in 2019 [Decision Resources, Inc web site]. June 28, 2010. Available at: Http://decisionresources.com/ News-And-Events/Press- Releases/Methicillin-Resistant-Staphylococcus-Aureus-062810. Accessed October 1, 2010
84. Brown SD, Traczewski MM. Comparative in vitro antimicrobial activities of torezolid (TR-700), the active moiety of a new oxazolidinone, torezolid phosphate (TR-701), determination of tentative disk diffusion interpretive criteria, and quality control ranges. Antimicrob Agents Chemother. 2010;54:2063-2069
85. Radezolid (RX-1741) [Rib-X Pharmaceuticals, Inc web site]. Available at: Http://www.rib-x.com/pipeline/rx-1741. Accessed October 1, 2010
86. Locke JB, Finn J, Hilgers M, et al. Structure-Activity relationships of diverse oxazolidinones for linezolidresistant staphylococcus aureus strains possessing the cfr methyltransferase gene or ribosomal mutations. Antimicrob Agents Chemother. 2010;54:5337-5343
87. Hooper DC. Mechanisms of action of antimicrobials: Focus on fluoroquinolones. Clin Infect Dis. 2001;32(suppl 1): S9-S15
88. Delafloxacin (RX-3341) [Rib-X Pharmaceuticals, Incweb site].Available at: Http://www.rib-x.com/pipeline/rx-3341. Accessed October 1, 2010
89. Rib-X Pharmaceuticals presents data supporting Delafloxacin as a potential best-in-class Fluoroquinolone at ICAAC [Rib-X Pharmaceuticals web site]. September 13, 2010. Available at: Http://www.rib-x.com/news-and- events/release-2010-09-14. Accessed November 22, 2010
90. Finafloxacin [MerLion Pharma web site]. Available at: Http://www.merlionpharma.com/node/16. Accessed October 1, 2010
91. Murray L, ed. Red Book and Updates. Montvale, NJ: Thompson Healthcare Inc.; 2010